Stock Events

Stock Events

Lisata Therapeutics 

$4.87
0
-$0.11-2.21% Wednesday 04:00

Statistics

Day High
4.87
Day Low
4.87
52W High
-
52W Low
-
Volume
96
Avg. Volume
-
Mkt Cap
42.96M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.54
-0.52
-0.51
-0.49
Expected EPS
N/A
Actual EPS
N/A

Financials

-1,998.5%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
2MRevenue
-39.97MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LSTA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, overlapping with Lisata's focus on novel treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for genetically defined diseases, competing in the genetic disorder treatment space.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics is involved in the discovery and development of RNA-based therapeutics, targeting conditions similar to those Lisata aims at.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals concentrates on creating new treatments for cystic fibrosis and other serious diseases, potentially competing in therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovative biologics, directly competing in the biopharmaceutical space for rare diseases.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurology, rare diseases, and autoimmune conditions, areas that might overlap with Lisata's therapeutic targets.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech giant with a broad portfolio that includes treatments for serious illnesses, possibly competing in some areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a diverse range of products, including for rare diseases, which could place it in competition with Lisata.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk specializes in diabetes care and other serious chronic conditions, potentially competing in the broader healthcare market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a wide-ranging portfolio that includes treatments for rare diseases and other serious conditions, making it a competitor in various therapeutic areas.

About

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Show more...
CEO
ISIN
US1280583022

Listings

LSE
GB
0HS8.LSE
F
DE
8NE.F
XNAS
US
LSTA
BOATS
BOATS
LSTA.BOATS

0 Comments

Share your thoughts

FAQ

What is Lisata Therapeutics stock price today?▼
The current price of LSTA.BOATS is $4.87 USD — it has decreased by -2.21% in the past 24 hours. Watch Lisata Therapeutics stock price performance more closely on the chart.
What is Lisata Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lisata Therapeutics stocks are traded under the ticker LSTA.BOATS.
What is Lisata Therapeutics market cap?▼
Today Lisata Therapeutics has the market capitalization of 42.96M
When is the next Lisata Therapeutics earnings date?▼
Lisata Therapeutics is going to release the next earnings report on May 07, 2026.
What is Lisata Therapeutics revenue for the last year?▼
Lisata Therapeutics revenue for the last year amounts to 2M USD.
What is Lisata Therapeutics net income for the last year?▼
LSTA.BOATS net income for the last year is -39.97M USD.
When did Lisata Therapeutics complete a stock split?▼
Lisata Therapeutics has not had any recent stock splits.